Lowry Frequently Asked Questions

Why should our company be considering pharmaceutical markets outside our own direct territory?

Two main reasons: patients and revenue.

Patients are global and well-educated about new medicinal treatments; the patient’s physician might ask Lowry Pharma (or even approach your directly) to obtain your drug on an unlicensed basis; we can supply unlicenced medicines via a Named Patient Supply (NPS) programme in an ethical and legal manner. The NHS Hospitals have budgets to pay for unlicensed medicines. A NPS program might be advantageous to implement prior to licensing (registration) and subsequent reimbursement of your product.

The UK is a very valuable market: according to the most recent data from NHS Digital, in 2019/20 the overall drugs cost at list price in the NHS was £20.9 billion. This is an increase of 9.9% from £19 billion in 2018/19. Hospital drug use accounted for just over half (55.9%) of the total at £11.7 billion (2019/20).

Why don’t I register and reimburse my medicine myself and engage a 3rd party logistics provider?

This is an option, in fact, Mawdsleys operates a very successful 3PL and 4PL business. However, it might be you wish to direct your resources elsewhere and outsource to a company who can deliver all the services you need, create a winning commercial strategy for the unique UK market and who has well established relationships with the NHS customer.

Why consider a separate, specialist partner for the UK?

From 1st January 2021, the UK left the European Union (EU). As a result of Brexit, the MHRA took on regulatory autonomy for the UK market and already new, unique regulatory pathways are being introduced. A pan-European approach to commercialise your medicine (that includes the UK) is now much harder to consider given the separation of EU vs UK regulatory environment and the uniqueness of the National Health Service as a customer.

If I choose to work with a local partner what key attributes should I look for?

Financially stable, market pedigree, physical infrastructure, market access and market knowledge, regulatory experience, business and market intelligence.

We have a drug (or even portfolio!) that we wish to divest – would Lowry Pharma be interested?

Yes, we would be happy to discuss the procurement of any hospital prescription medicines you wish to divest. You may seek to divest drugs that no longer fit into your portfolio or you are considering discontinuing; Lowry Pharma would be interested to consider any opportunity.

Does Lowry Pharma use third party vendors?

We do. Carefully chosen 3rd party vendors who are the best in their field extend our virtual team with a wide range of skills and experience. We have the ability to utilise these resources depending each projects unique requirements. This allows Lowry Pharma to deliver at the highest level for you for regulatory and pricing optimisation.

What products does Lowry Pharma commercialise?

Rare disease, oncology, first to market generics and other specialty hospital prescription medicines.

Specialty Pharma FAQ

Do you have a question you would like to ask us?

Why not come and talk to us?

info@lowrypharma.com

03707 200001

Lowry Pharma ®